Isofol Medical AB (publ)

Stockholm Stock Exchange ISOFOL.ST

Isofol Medical AB (publ) Capital Expenditure for the year ending December 31, 2023: USD 0.00

Isofol Medical AB (publ) Capital Expenditure is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Isofol Medical AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Isofol Medical AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Isofol Medical AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD 0.00, a 100.00% change year over year.
Isofol Medical AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -34.47 K, a 0.00% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: ISOFOL.ST

Isofol Medical AB (publ)

CEO	Mr. Petter Segelman Lindqvist
IPO Date	April 4, 2017
Location	Sweden
Headquarters	Biotech Center
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

Key trends

Past 5 years